{
    "clinical_study": {
        "@rank": "35298", 
        "arm_group": {
            "arm_group_label": "Single device arm", 
            "arm_group_type": "Other", 
            "description": "Mitral valve replacement"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to provide evidence of safety and effectiveness of the study\n      valve.   The rationale is to offer a replacement mitral valve for patients with anatomy that\n      is too small for the currently commercially available valves ranging in size from 16mm to\n      37mm."
        }, 
        "brief_title": "A Single Arm, Prospective, Multi-center Investigation of the SJM\u2122 Master Series 15mm Rotatable Mechanical Heart Valve", 
        "completion_date": {
            "#text": "May 2022", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Mitral Valve Disease", 
            "Damaged Mitral Valve", 
            "Malfunctioning Mitral Heart Valve", 
            "Mitral Valve Replacement"
        ], 
        "condition_browse": {
            "mesh_term": "Heart Valve Diseases"
        }, 
        "detailed_description": {
            "textblock": "The study is a single arm, prospective, non-randomized, multi-center clinical investigation.\n\n      The objective of this study is to evaluate the safety and effectiveness of the 15mm MHV in\n      subjects five years or less of age with a diseased, damaged, or malfunctioning mitral heart\n      valve.  The objective will be evaluated by assessing valve-related adverse events, subject\n      survival, subject growth, and echocardiogram assessment of hemodynamic function through the\n      five year follow-up visit as long as the valve remains implanted."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject requires mitral valve replacement.*\n\n          2. Subject's legally authorized representative gives written consent to participate in\n             the clinical study.\n\n          3. Subject is willing and able to return for data collection and follow-up for the\n             duration of the clinical study.\n\n               -  Subjects undergoing concomitant procedures (e.g. valve repair) are eligible for\n                  this study other than those noted in the exclusion criteria.\n\n        Exclusion Criteria:\n\n          1. Subject is > 5 years of age.\n\n          2. Subject has a contraindication to anticoagulant/antiplatelet medication.\n\n          3. Subject has a prosthetic valve(s) at a site other than the mitral valve prior to the\n             study procedure.*\n\n          4. Subject requires concomitant replacement of the tricuspid, pulmonary, or aortic\n             valve.\n\n          5. Subject has active endocarditis.\n\n          6. Subject has active myocarditis.\n\n          7. Subject has an acute preoperative neurological deficit or cardiac adverse event that\n             has not returned to baseline or stabilized \u2265 30 days prior to the study procedure.\n\n          8. Subject has a non-cardiac illness resulting in a life expectancy of < 1 year.\n\n          9. Subject has a known requirement for additional cardiac surgery within 12 months after\n             the study procedure.\n\n         10. Subject has been previously enrolled and implanted in this study.\n\n         11. Subject is participating in another study for an investigational drug and/or device.\n\n         12. Subject has any other medical condition that in the opinion of the Investigator will\n             interfere with the study results.\n\n               -  Subjects who have undergone a previous Ross procedure of the pulmonary valve are\n                  eligible for this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "5 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "Yes", 
        "id_info": {
            "nct_id": "NCT02097420", 
            "org_study_id": "CL06404"
        }, 
        "intervention": {
            "arm_group_label": "Single device arm", 
            "description": "Expanded access includes implantation of the SJM\u2122  Masters Series 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions", 
            "intervention_name": "Mitral valve replacement SJM\u2122  Masters Series 15mm Rotatable Mechanical Heart Valve", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Mitral valve", 
        "lastchanged_date": "March 26, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Single Arm, Prospective, Non-randomized, Multi Center Investigation of the SJM\u2122 Master Series 15mm Rotatable Mechanical Heart Valve", 
        "overall_contact": {
            "email": "mditch@sjm.com", 
            "last_name": "Mindy Ditch, MS, CCRP", 
            "phone": "651.756.5578"
        }, 
        "overall_contact_backup": {
            "email": "cbuelow@sjm.com", 
            "last_name": "Christina Buelow", 
            "phone": "651.756.6571"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The actuarial (Kaplan-Meier) rate of total valve-related adverse events experienced through 365 days post implant or until the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first.", 
                "measure": "Valve-related Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "365 days post implant"
            }, 
            {
                "description": "Survival at 12 months post implant or survival until the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first.", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }, 
            {
                "description": "Peak gradient as assessed by echocardiography at 12 months post implant or when the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first.", 
                "measure": "Peak Gradient", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }, 
            {
                "description": "Mean gradient as assessed by echocardiography at 12 months post implant or when the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first.", 
                "measure": "Mean Gradient", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }, 
            {
                "description": "Valvular regurgitation as assessed by echocardiography at 12 months post implant or when the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first.", 
                "measure": "Valvular Regurgitation", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097420"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Increase in percentile ranking on the CDC growth chart for height at 12 months post implant or until the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first, compared to baseline.", 
                "measure": "Height Percentile Ranking", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }, 
            {
                "description": "Increase in percentile ranking on the CDC growth chart for weight at 12 months post implant or until the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first, compared to baseline.", 
                "measure": "Weight Percentile Ranking", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }, 
            {
                "description": "Effective orifice area (EOA) as assessed by echocardiography at 12 months post implant or when the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first.", 
                "measure": "EOA (effective orifice area)", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }, 
            {
                "description": "EOA index as assessed by echocardiography at 12 months post implant or when the valve is removed/replaced due to anatomical growth of the subject, whichever occurs first.", 
                "measure": "EOA (effective orifice area) Index", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }, 
            {
                "description": "Performance index as assessed by electrocardiography at 12 months post implant or when the valve is removed/replaced due to anatomical growth of subject, whichever comes first.", 
                "measure": "Performance Index", 
                "safety_issue": "No", 
                "time_frame": "12 months post implant"
            }
        ], 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}